Health Economics›Multiple myeloma›Relapsed or refractory single agents

Relapsed or refractory single agents

Multiple myeloma · 14 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 5 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Venetoclax monotherapy Variant #01	—	R 219 762	28d	—	—	~2	~R 439 524 indirect	—
Carfilzomib monotherapy Variant #01	—	R 146 511	28d	—	~10.2 mo	~2	~R 223 075 PFS proxy · indirect	1
Daratumumab monotherapy Variant #01	—	R 84 235	28d	—	—	~13	~R 1 095 049 PFS proxy · indirect	1
Ixazomib monotherapy Variant #01	—	R 39 177	28d	~22.0 mo	—	~12	~R 470 130 PFS proxy · indirect	2
Vemurafenib monotherapy Variant #01	—	R 13 464	28d	~7.2 mo	~15.5 mo	~2	~R 26 928 PFS proxy · indirect	4
Thalidomide monotherapy Variant #04	—	R 8 341	28d	~23.0 mo	—	~2	~R 16 682 PFS proxy · indirect	1
Pomalidomide monotherapy Variant #01	—	R 4 782	28d	~2.7 mo	—	~2	~R 9 564 PFS proxy · indirect	1
Lenalidomide monotherapy Variant #01	—	R 2 178	28d	~41.0 mo	~113.8 mo	~24	~R 52 272 PFS proxy · indirect	4
Talquetamab monotherapy Variant #01 Partial	—	—	7d	—	—	~2	—	—
Elranatamab monotherapy Variant #01 Partial	—	—	7d	—	—	~23	—	—
Daratumumab and hyaluronidase monotherapy Variant #01 Partial	—	—	28d	—	—	~33	—	2
Idecabtagene vicleucel monotherapy Variant #01 Partial	—	—	—	~13.6 mo	—	~1	—	2
Ciltacabtagene autoleucel monotherapy Variant #01 Partial	—	—	—	—	—	~1	—	3
Teclistamab monotherapy Variant #01 Partial	—	—	28d	—	—	~2	—	—

14 of 14 regimens shown